Hyperuricemia and cardiovascular risk: gut microbiota as a key link in pathogenesis and a new target for therapy

Hyperuricemia is a significant and independent risk factor for cardiovascular diseases. In recent years, scientists have been paying attention to the gut microbiota and its impact on various processes in the human body. Currently, there is evidence of the important role of the microbiota in the pathogenesis of hyperuricemia. An increase in the number of pathogenic microflora contributes to chronic inflammation and an increase in uric acid levels through the mechanisms of purine metabolism. The purpose of this review is to analyze and systematize current data on the impact of the intestinal microbiota on the pathogenesis of hyperuricemia and cardiovascular risk. The article discusses promising methods for correcting hyperuricemia, such as lifestyle modification, fecal microbiota transplantation, probiotics, and postbiotics. The review highlights the need for further research on the microbiota as a key factor in the pathogenesis of hyperuricemia and the development of new and innovative therapeutic strategies.

1. Vladimirov S.A., Eliseev M.S., Ilyinykh E.V., Marusenko I.M., Chichasova N.V., Yakupova S.P., Clinical Guidelines of the Russian Ministry of Health. Gout, 2018. Accessed in 2025. (In Russ.)]https://library.mededtech.ru/rest/documents/cr_174/

2. Wang Y, Li S, Li X, et al. (2025) Association between prebiotic, probiotic consumption and hyperuricemia in U.S. adults: a crosssectional study from NHANES 2011–2018. Front. Nutr. 12:1492708. DOI: 10.3389/fnut.2025.1492708

3. Du L, Zong Y, Li H, et al.. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024 Aug 28;9(1):212. PMID: 39191722; PMCID: PMC11350024. DOI: 10.1038/s41392-024-01916-y.

4. Shabalin VV, Grinstein YuI, Ruf RR, Samsonov NS. Asymptomatic hyperuricemia: obvious, controversial, hypothetical. Russian Journal of Preventive Medicine. 2023;26(7):103-109. (In Russ.) DOI: 10.17116/profmed202326071103

5. Yanai H, Adachi H, Hakoshima M, et al. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. Int J Mol Sci. 2021 Aug 26;22(17):9221. PMID: 34502127; PMCID: PMC8431537. DOI: 10.3390/ijms22179221.

6. Saito Y, Tanaka A, Node K, et al. Uric acid and cardiovascular disease: A clinical review. J Cardiol. 2021 Jul;78(1):51-57. Epub 2020 Dec 30. PMID: 33388217. DOI: 10.1016/j.jjcc.2020.12.013.

7. Padda J, Khalid K, Padda S, et al. Hyperuricemia and Its Association With Ischemic Stroke. Cureus. 2021 Sep 21;13(9):e18172. PMID: 34703698; PMCID: PMC8530529. DOI: 10.7759/cureus.18172.

8. Xu J, Zhao J, Gu J, et al. Serum uric acid levels as a causal factor in hypertension: Insights from Mendelian randomization analysis. Clin Exp Hypertens. 2025 Dec;47(1):2496514. Epub 2025 May 5. PMID: 40325623. DOI: 10.1080/10641963.2025.2496514.

9. Wang Z, Li Y, Liao W, et al. (2022) Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout. Front. Cell. Infect. Microbiol. 12:935723. DOI: 10.3389/fcimb.2022.935723

10. Danve A, Sehra ST, Neogi T. Role of diet in hyperuricemia and gout. Best Pract Res Clin Rheumatol. 2021 Dec;35(4):101723. Epub 2021 Nov 19. PMID: 34802900; PMCID: PMC8678356. DOI: 10.1016/j.berh.2021.101723.

11. Xu YX, Liu LD, Zhu JY, et al. Alistipes indistinctus-derived hippuric acid promotes intestinal urate excretion to alleviate hyperuricemia. Cell Host Microbe. 2024 Mar 13;32(3):366-381.e9. Epub 2024 Feb 26. PMID: 38412863. DOI: 10.1016/j.chom.2024.02.001.

12. Guo, H., Chen, Y., Dong, W. et al. Fecal Coprococcus, hidden behind abdominal symptoms in patients with small intestinal bacterial overgrowth. J Transl Med 22, 496 (2024). DOI: 10.1186/s12967-024-05316-2

13. Cheng J and Zhou J (2024) Unraveling the gut health puzzle: exploring the mechanisms of butyrate and the potential of High-Amylose Maize Starch Butyrate (HAMSB) in alleviating colorectal disturbances. Front. Nutr. 11:1285169. DOI: 10.3389/fnut.2024.1285169

14. Verhaar BJH, Prodan A, Nieuwdorp M, et al. Gut Microbiota in Hypertension and Atherosclerosis: A Review. Nutrients. 2020 Sep 29;12(10):2982. PMID: 33003455; PMCID: PMC7601560. DOI: 10.3390/nu12102982.

15. Ren L., Wang S., Liu S., et al. Postbiotic Pediococcus acidilactici GQ01, a novel probiotic strain isolated from natural fermented oat juice, attenuates hyperuricemia in mice by modulating uric acid metabolism and gut microbiota. Food. 2024. March 18. 13 (6): 923. PMID: 38540913; PMCID: PMC10969656. DOI: 10.3390/foods13060923.

16. Lopez-Siles M, Duncan SH, Garcia-Gil LJ, et al. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017 Apr;11(4):841-852. Epub 2017 Jan 3. PMID: 28045459; PMCID: PMC5364359. DOI: 10.1038/ismej.2016.176.

17. Yang, HT., Jiang, Zh., Yang, Y. et al. Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe. Cell Commun Signal 22, 54 (2024). DOI: 10.1186/s12964-023-01464-y

18. Miyajima Y, Karashima S, Mizoguchi R, et al. Prediction and causal inference of hyperuricemia using gut microbiota. Sci Rep. 2024 Apr 30;14(1):9901. PMID: 38688923; PMCID: PMC11061287. DOI: 10.1038/s41598-024-60427-6.

19. Choroszy M, Litwinowicz K, Bednarz R, et al. Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis. Metabolites. 2022 Nov 23;12(12):1165. PMID: 36557203; PMCID: PMC9788186. DOI: 10.3390/metabo12121165.

20. Zhou Y, Zeng Y, Wang R, et al. Resveratrol Improves Hyperuricemia and Ameliorates Renal Injury by Modulating the Gut Microbiota. Nutrients. 2024 Apr 7;16(7):1086. PMID: 38613119; PMCID: PMC11013445. DOI: 10.3390/nu16071086.

21. Cai JR, Chen XW, He YJ, et al. Washed microbiota transplantation reduces serum uric acid levels in patients with hyperuricaemia. World J Clin Cases. 2022 Apr 16;10(11):3401-3413. PMID: 35611199; PMCID: PMC9048544. DOI: 10 .12998/wjcc.v10.i11.3401.

22. Qian B, Zhang K, Li Y, et al.. Update on gut microbiota in cardiovascular diseases. Front Cell Infect Microbiol. 2022 Nov 10;12:1059349. PMID: 36439214; PMCID: PMC9684171. DOI: 10.3389/fcimb.2022.1059349.

23. Zeng L, Deng Y, He Q, et al. (2022) Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials. Front. Immunol. 13:961325. DOI: 10.3389/fimmu.2022.961325

24. Li, X., Cui, J., Ding, Z. et al. Klebsiella pneumoniae-derived extracellular vesicles impair endothelial function by inhibiting SIRT1. Cell Commun Signal 23, 21 (2025). DOI: 10.1186/s12964-024-02002-0

25. Mazidi M, Shekoohi N, Covic A, et al. Adverse Impact of Desulfovibrio spp. and Beneficial Role of Anaerostipes spp. on Renal Function: Insights from a Mendelian Randomization Analysis. Nutrients. 2020 Jul 25;12(8):2216. PMID: 32722370; PMCID: PMC7468709. DOI: 10.3390/nu12082216.

26. Sun Y., Wu D., Zeng W., et al. (2021) The Role of Arachidonic Acid Metabolism Disorder Caused by Intestinal Dysbiosis in Inflammation in Atherosclerosis. Front. Cell. Infect. Microbiol. 11:618265. DOI: 10.3389/fcimb.2021.618265

27. Sayols-Baixeras S, Dekkers KF, Baldanzi G, et al. Streptococcus Species Abundance in the Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort. Circulation. 2023 Aug 8;148(6):459-472. Epub 2023 Jul 12. PMID: 37435755; PMCID: PMC10399955. DOI: 10.1161/CIRCULATIONAHA.123.063914.

28. Dong Y, Xu R, Chen X, et al. 2023. Characterization of gut microbiota in adults with coronary atherosclerosis. PeerJ 11:e15245 DOI: 10.7717/peerj.15245

29. Ortega-Madueño I., Modrego J., Gómez-Gordo R., et al. Relación entre la cuantificación de calcio coronario y la composición de la microbiota intestinal en sujetos sin enfermedad cardiovascular previa: estudio piloto, Clínica e Investigación en Arteriosclerosis, Volume 34, Issue 4, 2022, Pages 205-215, ISSN 0214-9168, DOI: 10.1016/j.arteri.2021.11.008.

30. Wang, Z., Peters, B.A., Bryant, M. et al. Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection. Microbiome 11, 119 (2023). DOI: 10.1186/s40168-023-01566-2

31. You, Y., Zhao, Y., Chen, M. et al. Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 15, 202 (2023). DOI: 10.1186/s13098-023-01182-y

32. Zhao R, Li Z, Sun Y, et al. Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment. Gut Microbes. 2022 JanDec;14(1):2070391. PMID: 35491895; PMCID: PMC9067508. DOI: 10.1080/19490976.2022.2070391.

33. Nutrition and Clinical Dietetics / edited by V.A. Tutelyan and D.B. Nikityuk. Moscow: GEOTAR-Media, 2020. — 656 p. (Series “National Guidelines”) — ISBN 978-5-9704-5352-0 (In Russ.)

34. Wang R, Halimulati M, Huang X, et al. Sulforaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia. J Adv Res. 2023 Oct;52:19-28. Epub 2022 Nov 10. PMID: 36371056; PMCID: PMC10555773. DOI: 10.1016/j.jare.2022.11.003.

35. Zhang T, Liu W, Gao S. Exercise and hyperuricemia: an opinion article. Ann Med. 2024 Dec;56(1):2396075. Epub 2024 Aug 26. PMID: 39183708; PMCID: PMC11348809. DOI: 10.1080/07853890.2024.2396075.

36. Lebedev P.A., Volova L.T., Osina N.K., Paranina E.V. NLRP3 Inflammasome- a new universal target of asymptomatic hyperuricemia and gout management. Rational Pharmacotherapy in Cardiology. 2024;20(3):331-339. EDN JQXOBW (In Russ.) DOI: 10.20996/1819-6446-2024-3018.

37. Hu Y, Shi Y, Chen H, et al. Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis. Front Immunol. 2022 Mar 2;13:858494. PMID: 35309342; PMCID: PMC8924517. DOI: 10.3389/fimmu.2022.858494.

38. Tan, J., Dong, L., Jiang, Z. et al. Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling. J Transl Med 20, 382 (2022). DOI: 10.1186/s12967-022-03585-3

39. Ma L, Tu H, Chen T. Postbiotics in Human Health: A Narrative Review. Nutrients. 2023 Jan 6;15(2):291. PMID: 36678162; PMCID: PMC9863882. DOI: 10.3390/nu15020291.

40. Wendel U (2022) Assessing Viability and Stress Tolerance of Probiotics—A Review. Front. Microbiol. 12:818468. DOI: 10.3389/fmicb.2021.818468

41. Han S, Lu Y, Xie J, et al. (2021) Probiotic Gastrointestinal Transit and Colonization After Oral Administration: A Long Journey. Front. Cell. Infect. Microbiol. 11:609722. DOI: 10.3389/fcimb.2021.609722

42. Корниенко Е.А. Пробиотики, постбиотики и парапробиотики. Экспериментальная и клиническая гастроэнтерология. 2022;205(9): 240-250. РО!: 10.31146/1682-8658-есд-205-9-240- 250. DOI: 10.31146/1682-8658-ecg-205-9-240-250